Clinical Trial Update: Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating an anti-angiogenesis agent in combination with an EGFR-TKI for advanced non-squamous non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Xinqiao Hospital of Chongqing | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN